Published online May 14, 2014. doi: 10.3748/wjg.v20.i18.5274
Revised: December 30, 2013
Accepted: January 20, 2014
Published online: May 14, 2014
Processing time: 240 Days and 12.5 Hours
The Maastricht IV/Florence Consensus Report and the Second Asia-Pacific Consensus Guidelines strongly recommend eradication of Helicobacter pylori (H. pylori) in patients with previous gastric neoplasia who have undergone gastric surgery. However, the guidelines do not mention optimal timing, eradication regimens, diagnostic tools, and follow-up strategies for patients undergoing gastrectomy and do not indicate if eradication of H. pylori reduces the risk of marginal ulcer or stump cancer in the residual stomach after gastrectomy. The purpose of this review is to provide an update which may help physicians to properly manage H. pylori infection in patients who have undergone gastric surgery. This review focuses on (1) the microenvironment change in the stomach after gastrectomy; (2) the phenomenon of spontaneous clearance of H. pylori after gastrectomy; (3) the effects of H. pylori on gastric atrophy and intestinal metaplasia after gastrectomy; (4) incidence and clinical features of ulcers developing after gastrectomy; (5) does eradication of H. pylori reduce the risk of gastric stump cancer in the residual stomach? (6) does eradication of H. pylori reduce the risk of secondary metachronous gastric cancer in the residual stomach? and (7) optimal timing and regimens for H. pylori eradication, diagnostic tools and follow-up strategies for patients undergoing gastrectomy.
Core tip: For patients undergoing gastric surgery due to acute complications of peptic ulcer diseases or gastric cancer, this surgical procedure may increase the occurrence of biliary enterogastric reflux and potentially inhibit the growth of Helicobacter pylori (H. pylori) in the stomach. Bile reflux and H. pylori infection appear to have a synergistic effect on cell proliferation in the gastric remnant and may explain the increased risk of cancer after gastrectomy. First-line triple therapy is effective for the eradication of H. pylori in gastrectomized patients. Serology is the only test that is not affected by local changes in the stomach, and could be used to avoid the false-negative results obtained with other tests.